title: Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.
abstract: BACKGROUND
  Parkinson's disease (PD) is a progressive neurological disorder for which, at present, there is no cure. Current therapy is largely based on the use of dopamine agonists and dopamine replacement therapy, designed to control the signs and symptoms of the disease. The majority of current treatments are administered in tablet form and can involve multiple daily doses, which may contribute to sub-optimal compliance. Previous studies with small groups of patients suggest that non-compliance with treatment can result in poor response to therapy and may ultimately increase direct and indirect healthcare costs.
  
  
  OBJECTIVE
  To determine the extent of non-compliance within the general PD population in the USA as well as the patient characteristics and healthcare costs associated with compliance and non-compliance.
  
  
  METHODS
  A retrospective analysis from a managed care perspective was conducted using data from the USA PharMetrics patient-centric claims database. PharMetrics claims data were complete from 31 December 2005 to 31 December 2009. Patients were included if they had at least two diagnoses for PD between 31 December 2005 and 31 December 2008, were older than 18 years of age, were continuously enrolled for at least 12 months after the date of the most recent PD diagnosis, and had no missing or invalid data. The follow-up period was the most recent 12-month block of continuous enrollment that occurred between 2006 and 2009. Patients were required to have at least one PD-related prescription within the follow-up period. The medication possession ratio (MPR) was used to categorise patients as compliant or non-compliant. Direct all-cause annual healthcare costs for patients with PD were estimated for each patient, and regression analyses were conducted to determine predictors for non-compliance.
  
  
  RESULTS
  A total of 15,846 patients were included, of whom 46 % were considered to be non-compliant with their prescribed medication (MPR <0.8). Predictors of non-compliance included prescription of a medication administered in multiple daily doses (p < 0.0001), a period of <2 years since the initial PD diagnosis (p = 0.0002), a diagnosis of gastrointestinal disorder (p < 0.0001), and a diagnosis of depression (p < 0.0001). Non-compliance was also found to be related to age, with a lower odds of non-compliance in patients aged 41-80 years than in patients aged ≥81 years (p < 0.05). Although total drug mean costs were higher for compliant patients than non-compliant patients (driven mainly by the cost of PD-related medications), the mean costs associated with emergency room and inpatient visits were higher for patients non-compliant with their prescribed medication. Overall, the total all-cause annual healthcare mean cost was lower for compliant ($77,499) than for non-compliant patients ($84,949; p < 0.0001).
  
  
  CONCLUSIONS
  Non-compliance is prevalent within the general USA PD population and is associated with a recent PD diagnosis, certain comorbidities, and multiple daily treatment dosing. Non-compliance may increase the burden on the healthcare system because of greater resource usage compared with the compliant population. Treatments that require fewer daily doses may have the potential to improve compliance, which in turn could reduce the economic burden associated with PD.
authors: UCB Pharma, Allée de la Recherche 60, 1070, Brussels, Belgium.
authors: Florent F
authors: FF
authors: Richy
authors: Guilhem
authors: G
authors: Pietri
authors: Kimberly A
authors: KA
authors: Moran
authors: Emmanuelle
authors: E
authors: Senior
authors: Lydia E
authors: LE
authors: Makaroff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D016001:Confidence Intervals; D016208:Databases, Factual; D004358:Drug Therapy / Q000592:standards*; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D008329:Managed Care Programs; D008875:Middle Aged; D016017:Odds Ratio; D010300:Parkinson Disease / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D055815:Young Adult
references: Pharmacoeconomics. 2001;19(12):1185-97
references: 11772154
references: Case Manager. 2004 Sep-Oct;15(5):46-50; quiz 51
references: 15467645
references: Neurology. 2007 Jan 30;68(5):384-6
references: 17082464
references: Eur J Neurol. 2006 Nov;13(11):1170-85
references: 17038031
references: J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):249-51
references: 16421131
references: Neurology. 2000;54(11 Suppl 5):S21-3
references: 10854357
references: Curr Hypertens Rep. 1999 Dec;1(6):502-6
references: 10981113
references: Expert Opin Drug Deliv. 2009 Apr;6(4):389-404
references: 19382882
references: J Cardiovasc Pharmacol. 1996 Apr;27(4):563-70
references: 8847874
references: N Engl J Med. 2008 Dec 4;359(23):2468-76
references: 19052127
references: Drugs Aging. 2011 Dec 1;28(12):1015-7
references: 22117099
references: Neuropsychiatr Dis Treat. 2008 Feb;4(1):i-ii
references: 18728800
references: J Clin Pharmacol. 1992 Mar;32(3):277-83
references: 1564133
references: Mov Disord. 2010 Mar 15;25(4):474-80
references: 20131374
references: J Neurol Sci. 2010 Feb 15;289(1-2):115-8
references: 19793590
references: Expert Rev Neurother. 2012 Feb;12(2):239-48
references: 22288679
references: J Clin Epidemiol. 1997 May;50(5):619-25
references: 9180655
references: Am J Hosp Pharm. 1991 Sep;48(9):1978-88
references: 1928147
references: Mov Disord. 2005 Nov;20(11):1449-54
references: 16007641
references: J Parkinsons Dis. 2011;1(1):65-74
references: 23939257
references: N Engl J Med. 2000 May 18;342(20):1484-91
references: 10816186
references: Am J Geriatr Pharmacother. 2010 Aug;8(4):374-83
references: 20869623
references: Ther Deliv. 2011 May;2(5):611-22
references: 22833978
references: Mov Disord. 2005 Nov;20(11):1502-7
references: 16037924
references: Soc Sci Med. 1994 Aug;39(3):381-90
references: 7939855
references: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011
references: 18425859
references: BMJ. 2006 Jul 1;333(7557):15
references: 16790458
references: Expert Opin Drug Deliv. 2011 Mar;8(3):359-74
references: 21314492
references: Neurology. 2009 May 26;72(21 Suppl 4):S1-136
references: 19470958
references: Mov Disord. 2009 Apr 30;24(6):826-32
references: 19191340
references: Mov Disord. 2004 May;19(5):513-7
references: 15133814
references: Can J Neurol Sci. 2012 Jul;39(4 Suppl 4):S1-30
references: 23126020
references: Parkinsonism Relat Disord. 2010 Sep;16(8):513-6
references: 20605106
references: Patient Couns Health Educ. 1978 1st Quart;1(1):18-21
references: 10238880
references: Neurology. 2006 Apr 11;66(7):983-95
references: 16606909
references: CNS Drugs. 2004;18(9):547-60
references: 15222772
references: Psychol Med. 1976 Nov;6(4):599-601
references: 1005577
references: Arch Neurol. 2007 Aug;64(8):1083-8
references: 17698697
references: Am J Manag Care. 2010 Mar;16 Suppl Implications:S87-93
references: 20297871